AstraZeneca (NYSE: AZN) announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (BRILINTA(TM)) at the annual American Heart Association (AHA) Scientific Sessions in Orlando, FL,(1,2) with ONSET/OFFSET study results being simultaneously published in the medical journal Circulation.(3)

The ONSET/OFFSET data showed that treatment with ticagrelor (BRILINTA(TM)) achieved a more rapid onset of antiplatelet effect (41% IPA vs. 8% at 30 minutes; P